{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T20:21:38Z","timestamp":1786911698784,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"DOI":"10.7759\/cureus.109674","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:23:58Z","timestamp":1779801838000},"source":"Crossref","is-referenced-by-count":1,"title":["Avacopan-Associated Hepatotoxicity: Clinical Signal, Liver Injury Patterns, and Plausible Mechanisms"],"prefix":"10.7759","author":[{"given":"Luis Guillermo","family":"Herrera-Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Arguedas-Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeaustin","family":"Mora-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Zavaleta-Monestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne DR","year":"2021","unstructured":"Jayne DR, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021, 384:599-609. 10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"},{"key":"ref2","article-title":"Avacopan","year":"2024","unstructured":"Avacopan. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2024."},{"key":"ref3","unstructured":"ClinicalTrials.gov. A phase 3 clinical trial of CCX168 (avacopan) in patients with ANCA-associated vasculitis (ADVOCATE). (2025). Accessed: May 25, 2026: https:\/\/clinicaltrials.gov\/study\/NCT02994927."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70001","article-title":"Safety of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: combined data from three clinical trials","volume":"7","author":"Merkel PA","year":"2025","unstructured":"Merkel PA, George MD, Yue H, Popov T, Kronbichler A, Little MA, Jayne DR. Safety of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: combined data from three clinical trials. ACR Open Rheumatol. 2025, 7:e70001. 10.1002\/acr2.70001","journal-title":"ACR Open Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-025-00456-4","article-title":"Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan","volume":"9","author":"Tagami G","year":"2025","unstructured":"Tagami G, Yamaguchi M, Sugiyama H, et al.. Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan. BMC Rheumatol. 2025, 9:8. 10.1186\/s41927-025-00456-4","journal-title":"BMC Rheumatol"},{"key":"ref6","unstructured":"U.S. Food and Drug Administration. FDA identifies cases of serious liver injury in patients taking Tavneos (avacopan) for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. (2026). Accessed: April 24, 2026: https:\/\/www.fda.gov\/drugs\/drug-safety-communications\/fda-identifies-cases-serious-liver-injury-patients-taking-tavneo...."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2568971","article-title":"Post-marketing safety profile and clinical prioritization of adverse events with avacopan in ANCA-associated vasculitis: a FAERS pharmacovigilance analysis","volume":"47","author":"Yang Z","year":"2025","unstructured":"Yang Z, Wang C, Wei S, et al.. Post-marketing safety profile and clinical prioritization of adverse events with avacopan in ANCA-associated vasculitis: a FAERS pharmacovigilance analysis. Ren Fail. 2025, 47:2568971. 10.1080\/0886022X.2025.2568971","journal-title":"Ren Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/med4.70056","article-title":"The drug safety framework of avacopan: a pharmacovigilance study","volume":"4","author":"Chang T","year":"2026","unstructured":"Chang T, Xin X, Shao X, Pan D, Wang J. The drug safety framework of avacopan: a pharmacovigilance study. Med Adv. 2026, 4:77-89. 10.1002\/med4.70056","journal-title":"Med Adv"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1654735","article-title":"The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis","volume":"16","author":"Li Y","year":"2025","unstructured":"Li Y, Meng A, Wang Y. The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis. Front Immunol. 2025, 16:1654735. 10.3389\/fimmu.2025.1654735","journal-title":"Front Immunol"},{"key":"ref10","unstructured":"European Medicines Agency. Tavneos. (2025). Accessed: April 17, 2026: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tavneos."},{"key":"ref11","unstructured":"DailyMed. TAVNEOS- avacopan capsule. (2025). Accessed: April 24, 2026: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c93cbc0b-29a3-46a5-9c85-41815ea5cf4a&audience=consumer."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne DR","year":"2017","unstructured":"Jayne DR, Bruchfeld AN, Harper L, et al.. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017, 28:2756-67. 10.1681\/ASN.2016111179","journal-title":"J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel PA","year":"2020","unstructured":"Merkel PA, Niles J, Jimenez R, et al.. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020, 2:662-71. 10.1002\/acr2.11185","journal-title":"ACR Open Rheumatol"},{"key":"ref14","unstructured":"The Rheumatologist. Avacopan safety alert issued over cases of serious liver injury. (2026). Accessed: April 15, 2026: https:\/\/www.the-rheumatologist.org\/article\/avacopan-safety-alert-issued-over-cases-of-serious-liver-injury\/."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06376-8","article-title":"A case of rapid avacopan-induced liver injury in pediatric granulomatosis with polyangiitis","volume":"39","author":"Nishino T","year":"2024","unstructured":"Nishino T, Tomori S, Haruyama M, Takahashi K, Mimaki M. A case of rapid avacopan-induced liver injury in pediatric granulomatosis with polyangiitis. Pediatr Nephrol. 2024, 39:2919-22. 10.1007\/s00467-024-06376-8","journal-title":"Pediatr Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead285","article-title":"A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan","volume":"63","author":"Yamaguchi S","year":"2024","unstructured":"Yamaguchi S, Yamazaki M, Kido T, et al.. A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan. Rheumatology (Oxford). 2024, 63:e120-2. 10.1093\/rheumatology\/kead285","journal-title":"Rheumatology (Oxford)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7326\/aimcc.2024.0602","article-title":"Avacopan causing vanishing bile duct syndrome in an adult patient with microscopic polyangiitis","volume":"3","author":"Tang A","year":"2024","unstructured":"Tang A, Di Fonzo DM, Alsaddah S, Maedler-Kron C, Mendel A, Sebastiani G. Avacopan causing vanishing bile duct syndrome in an adult patient with microscopic polyangiitis. Ann Intern Med Clin Cases. 2024, 3:10.7326\/aimcc.2024.0602","journal-title":"Ann Intern Med Clin Cases"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15400","article-title":"Case report: avacopan-induced severe liver injury with prolonged jaundice and lipoprotein X-induced dyslipidemia","volume":"27","author":"Kioi Y","year":"2024","unstructured":"Kioi Y, Itotagawa E, Kawachi Y, et al.. Case report: avacopan-induced severe liver injury with prolonged jaundice and lipoprotein X-induced dyslipidemia. Int J Rheum Dis. 2024, 27:e15400. 10.1111\/1756-185X.15400","journal-title":"Int J Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042121","article-title":"Drug-induced liver injury due to avacopan improved by mycophenolate mofetil: a case report","volume":"104","author":"Yamashita R","year":"2025","unstructured":"Yamashita R, Izumi Y, Takane K, Kinoshita A, Hiramoto J. Drug-induced liver injury due to avacopan improved by mycophenolate mofetil: a case report. Medicine (Baltimore). 2025, 104:e42121. 10.1097\/MD.0000000000042121","journal-title":"Medicine (Baltimore)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae689","article-title":"Drug-induced liver injury related to avacopan therapy","volume":"64","author":"Mori K","year":"2025","unstructured":"Mori K, Shirai T, Mutoh T, et al.. Drug-induced liver injury related to avacopan therapy. Rheumatology (Oxford). 2025, 64:2533-40. 10.1093\/rheumatology\/keae689","journal-title":"Rheumatology (Oxford)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead509","article-title":"Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan","volume":"63","author":"Kojima K","year":"2024","unstructured":"Kojima K, Fukui S, Tanigawa M, et al.. Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan. Rheumatology (Oxford). 2024, 63:e101-3. 10.1093\/rheumatology\/kead509","journal-title":"Rheumatology (Oxford)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5043-24","article-title":"Vanishing bile duct syndrome caused by a treatment regimen including avacopan for microscopic polyangiitis","volume":"65","author":"Hishinuma M","year":"2026","unstructured":"Hishinuma M, Hasegawa M, Minatoguchi S, et al.. Vanishing bile duct syndrome caused by a treatment regimen including avacopan for microscopic polyangiitis. Intern Med. 2026, 65:1017-22. 10.2169\/internalmedicine.5043-24","journal-title":"Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0340","article-title":"Absence of glucocorticoids concomitant with avacopan and subsequent liver injury in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"51","author":"Uchida T","year":"2024","unstructured":"Uchida T, Fukui S, Iwamoto N, et al.. Absence of glucocorticoids concomitant with avacopan and subsequent liver injury in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2024, 51:1146-8. 10.3899\/jrheum.2024-0340","journal-title":"J Rheumatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6273-25","article-title":"Avacopan-associated liver injury in Japanese patients with anca-associated vasculitis: clinical, genetic, and mechanistic perspectives","volume":"65","author":"Hishida E","year":"2026","unstructured":"Hishida E, Nagata D. Avacopan-associated liver injury in Japanese patients with anca-associated vasculitis: clinical, genetic, and mechanistic perspectives. Intern Med. 2026, 65:941-2. 10.2169\/internalmedicine.6273-25","journal-title":"Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-025-00555-2","article-title":"Avacopan is effective in inducing remission for MPA\/GPA, regardless of changes in serum C5a levels: a single-center study in Japan","volume":"9","author":"Ushio Y","year":"2025","unstructured":"Ushio Y, Shimada H, Wakiya R, et al.. Avacopan is effective in inducing remission for MPA\/GPA, regardless of changes in serum C5a levels: a single-center study in Japan. BMC Rheumatol. 2025, 9:99. 10.1186\/s41927-025-00555-2","journal-title":"BMC Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan G","year":"2015","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015, 17:14. 10.3390\/ijms17010014","journal-title":"Int J Mol Sci"},{"key":"ref27","article-title":"Adverse drug reaction probability Scale (Naranjo) in drug induced liver injury","year":"2019","unstructured":"Adverse drug reaction probability Scale (Naranjo) in drug induced liver injury. LiverTox\u00ae. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2019."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14046","article-title":"RECAM-J 2023-validation and development of the Japanese version of RECAM for the diagnosis of drug-induced liver injury","volume":"54","author":"Tanaka A","year":"2024","unstructured":"Tanaka A, Tsuji K, Komiyama Y, et al.. RECAM-J 2023-validation and development of the Japanese version of RECAM for the diagnosis of drug-induced liver injury. Hepatol Res. 2024, 54:503-12. 10.1111\/hepr.14046","journal-title":"Hepatol Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/490984-avacopan-associated-hepatotoxicity-clinical-signal-liver-injury-patterns-and-plausible-mechanisms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:24:01Z","timestamp":1779801841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/490984-avacopan-associated-hepatotoxicity-clinical-signal-liver-injury-patterns-and-plausible-mechanisms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.109674","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}